$BDTX

$1.75 +$0.06 (3.55%) Close

$BDTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$BDTX Management Team

Mr. Brent Hatzis-Schoch

Chief Operating Officer

General Counsel

Age 60

Compensation $1.405M USD

Sex Male

Dr. Mark Velleca

Chairman of the Board

President

Chief Executive Officer

Age 61

Compensation $2.855M USD

Sex Male

Dr. Elizabeth Buck

Co-Founder

Chief Scientific Officer

Age 50

Compensation -

Sex Female

Ms. Erika Jones

Senior Vice President - Finance

Principal Financial Officer and Principal Accounting Officer

Age 40

Compensation -

Sex Female

Ms. Melanie Morrison

Chief Development Officer

Age 50

Compensation -

Sex Female

Dr. Sergey Yurasov

Chief Medical Officer

Age 56

Compensation $1.515M USD

Sex Male

Name / Title	Age	Compensation	Sex
Mr. Brent Hatzis-Schoch Chief Operating Officer General Counsel	60	$1.405M USD	Male
Dr. Mark Velleca Chairman of the Board President Chief Executive Officer	61	$2.855M USD	Male
Dr. Elizabeth Buck Co-Founder Chief Scientific Officer	50	-	Female
Ms. Erika Jones Senior Vice President - Finance Principal Financial Officer and Principal Accounting Officer	40	-	Female
Ms. Melanie Morrison Chief Development Officer	50	-	Female
Dr. Sergey Yurasov Chief Medical Officer	56	$1.515M USD	Male

Board of Directors

From the proxy statement filed Apr 29, 2026

Directors

serving now

Independent

0 of 1

stated in the proxy; 6 not stated

Average tenure

5.4 years

from year joined

CEO also chairs the board

Yes

Mark A. Velleca, M.D., Ph.D.

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Shannon Campbell	60	2024 2 years	Not stated	Compensation Committee	None stated	$108,030
Kapil Dhingra	66	2021 5 years	Not stated	None stated	Replimune, Inc., Median Technologies SA	$105,030
Prakash Raman	56	2024 2 years	Not stated	Audit Committee	NAYA Biosciences, Inc.	Not stated
Mark A. Velleca, M.D., Ph.D. Board chair, CEO	62	2021 5 years	Not independent	None stated	None stated	Paid as CEO
Ali Behbahani, M.D.	49	2018 8 years	Not stated	None stated	NKarta, Inc.	$114,530
Garry E. Menzel, Ph.D.	61	2017 9 years	Not stated	None stated	Stoke Therapeutics, Inc.	$117,030
Samarth Kulkarni, Ph.D. Lead independent director	47	2019 7 years	Not stated	Nominating and Corporate Governance Committee	Repare Therapeutics Inc.	$126,030

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 29, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Comments

Company Executives

$BDTX Management Team

Mr. Brent Hatzis-Schoch

Dr. Mark Velleca

Dr. Elizabeth Buck

Ms. Erika Jones

Ms. Melanie Morrison

Dr. Sergey Yurasov

Board of Directors

Related-party transactions

No related-party transactions disclosed